Fortress Biotech Inc (NASDAQ:FBIO) SVP George Avgerinos sold 12,000 shares of the business’s stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $3.55, for a total transaction of $42,600.00. Following the completion of the sale, the senior vice president now directly owns 352,495 shares in the company, valued at approximately $1,251,357.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
George Avgerinos also recently made the following trade(s):
- On Tuesday, December 12th, George Avgerinos sold 25,593 shares of Fortress Biotech stock. The stock was sold at an average price of $3.59, for a total transaction of $91,878.87.
Fortress Biotech Inc (FBIO) opened at $3.46 on Tuesday. Fortress Biotech Inc has a fifty-two week low of $1.88 and a fifty-two week high of $5.13. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.69 and a quick ratio of 2.69.
Large investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC acquired a new position in shares of Fortress Biotech in the third quarter valued at $101,000. State of Wisconsin Investment Board acquired a new position in shares of Fortress Biotech in the second quarter valued at about $119,000. National Asset Management Inc. grew its stake in shares of Fortress Biotech by 38.4% in the second quarter. National Asset Management Inc. now owns 28,850 shares of the biopharmaceutical company’s stock valued at $138,000 after acquiring an additional 8,000 shares in the last quarter. Strs Ohio acquired a new position in shares of Fortress Biotech in the second quarter valued at about $164,000. Finally, Rhumbline Advisers grew its stake in shares of Fortress Biotech by 2.8% in the second quarter. Rhumbline Advisers now owns 38,846 shares of the biopharmaceutical company’s stock valued at $185,000 after acquiring an additional 1,075 shares in the last quarter. Hedge funds and other institutional investors own 12.05% of the company’s stock.
FBIO has been the topic of a number of research reports. HC Wainwright set a $11.00 price objective on shares of Fortress Biotech and gave the stock a “buy” rating in a research report on Tuesday, December 12th. Zacks Investment Research raised shares of Fortress Biotech from a “sell” rating to a “hold” rating in a research report on Tuesday, October 10th. Finally, ValuEngine lowered shares of Fortress Biotech from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $11.00.
TRADEMARK VIOLATION WARNING: This report was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://sportsperspectives.com/2017/12/19/fortress-biotech-inc-fbio-svp-george-avgerinos-sells-12000-shares-of-stock.html.
Fortress Biotech Company Profile
Fortress Biotech, Inc, formerly Coronado Biosciences, Inc, is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products.
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.